Frias Juan C, Ma Yanqing, Williams Kevin Jon, Fayad Zahi A, Fisher Edward A
Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai School of Medicine, New York, New York 10029, USA.
Nano Lett. 2006 Oct;6(10):2220-4. doi: 10.1021/nl061498r.
The need for more specific and selective contrast agents for magnetic resonance imaging motivated us to prepare a new nanoparticle agent based on high-density lipoproteins (HDL). This second generation contrast agent can be prepared in three different ways. The HDL nanoparticles (rHDL) were fully characterized by FPLC and gel electrophoresis. The flexibility of the platform also allows us to incorporate optical probes into rHDL for localization ex vivo by confocal fluorescence microscopy. The contrast-agent-containing nanoparticles were injected into mice that develop atherosclerotic lesions. Magnetic resonance imaging of the animals showed clear enhancement of the atherosclerotic plaques.
对用于磁共振成像的更具特异性和选择性的造影剂的需求促使我们制备一种基于高密度脂蛋白（HDL）的新型纳米颗粒造影剂。这种第二代造影剂可以通过三种不同的方式制备。通过快速蛋白质液相色谱法（FPLC）和凝胶电泳对高密度脂蛋白纳米颗粒（重组高密度脂蛋白，rHDL）进行了全面表征。该平台的灵活性还使我们能够将光学探针整合到重组高密度脂蛋白中，以便通过共聚焦荧光显微镜进行离体定位。将含有造影剂的纳米颗粒注射到患有动脉粥样硬化病变的小鼠体内。对这些动物进行的磁共振成像显示动脉粥样硬化斑块有明显增强。
